Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer

Document Type

Article

Publication Date

9-13-2016

Publication Title

British Journal of Cancer

Department

Thayer School of Engineering

Additional Department

Geisel School of Medicine

Abstract

Aminolevulinic acid (ALA)-based photodynamic therapy (PDT) provides selective uptake and conversion of ALA into protoporphyrin IX (PpIX) in actinic keratosis and squamous cell carcinoma, yet large response variations in effect are common between individuals. The aim of this study was to compare pre-treatment strategies that increase the therapeutic effect, including fractionated light delivery during PDT (fPDT) and use of iron chelator desferrioxamine (DFO), separately and combined.

DOI

10.1038/bjc.2016.267

Share

COinS